You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Datopotamab Deruxtecan

Showing 51 - 75 of 80
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

PROVIDENCE - Real-world Study in HER2-positive Unresectable or

Not yet recruiting
  • Breast Neoplasms
  • +2 more
    • (no location specified)
    Oct 7, 2022

    Extensive-stage Small-cell Lung Cancer Trial in Japan, United States (DS-7300a)

    Recruiting
    • Extensive-stage Small-cell Lung Cancer
    • Ifinatamab Deruxtecan (I-DXd)
    • Jacksonville, Florida
    • +22 more
    Jan 10, 2023

    Nonsquamous NSCLC, EGFR L858R, EGFR Exon 19 Deletion Trial in Worldwide (Patritumab Deruxtecan, Platinum-based chemo)

    Recruiting
    • Nonsquamous Non-small Cell Lung Cancer
    • +2 more
    • Patritumab Deruxtecan
    • Platinum-based chemotherapy
    • Anchorage, Alaska
    • +182 more
    Jan 17, 2023

    Advanced or Metastatic Breast Cancer Trial in Worldwide (Trastuzumab deruxtecan, Capecitabine, Paclitaxel)

    Recruiting
    • Advanced or Metastatic Breast Cancer
    • Trastuzumab deruxtecan
    • +3 more
    • Scottsdale, Arizona
    • +343 more
    Jul 22, 2022

    Breast Cancer Trial in Sweden (Trastuzumab deruxtecan, Docetaxel, Paclitaxel)

    Not yet recruiting
    • Breast Cancer
    • Trastuzumab deruxtecan
    • +9 more
    • Malmö, Sweden
    • +6 more
    Jun 8, 2023

    Stomach Tumor Trial (Trastuzumab deruxtecan, Afatinib)

    Not yet recruiting
    • Stomach Neoplasm
    • (no location specified)
    Oct 16, 2023

    Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Tumor in the Brain Trial in Duarte

    Recruiting
    • Anatomic Stage IV Breast Cancer AJCC v8
    • +2 more
    • Copper Cu 64-DOTA-Trastuzumab
    • +4 more
    • Duarte, California
      City of Hope Medical Center
    Nov 22, 2022

    HER2-positive Breast Cancer Trial in Coudekerque-Branche

    Recruiting
    • HER2-positive Breast Cancer
      • Coudekerque-Branche, France
        Clinique des Flandres
      Jan 6, 2022

      Breast Cancer Trial in Spain (U3 1402)

      Recruiting
      • Breast Cancer
      • U3 1402
      • Badalona, Barcelona, Spain
      • +9 more
      Apr 1, 2022

      Metastatic Breast Cancer Trial in Rome (HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and

      Recruiting
      • Metastatic Breast Cancer
      • HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment
      • Rome, Italy
        Fondazione Policlinico A. Gemelli - IRCCS
      Jun 22, 2023

      Breast Cancer Trial in Worldwide (Trastuzumab Deruxtecan)

      Recruiting
      • Breast Cancer
      • Trastuzumab Deruxtecan
      • San Diego, California
      • +90 more
      Jul 19, 2022

      HER2 Positive Breast Cancer Trial in United States (tucatinib, trastuzumab deruxtecan)

      Recruiting
      • HER2 Positive Breast Cancer
      • Birmingham, Alabama
      • +32 more
      Oct 26, 2022

      NSCLC Trial in Worldwide (Trastuzumab deruxtecan)

      Active, not recruiting
      • Non-Small Cell Lung Cancer
      • Trastuzumab deruxtecan
      • Aurora, Colorado
      • +47 more
      Apr 27, 2022

      Adenocarcinoma, Gastric, Tumor, Breast Trial in Taipei (DS-8201a)

      Completed
      Has Results
      • Adenocarcinoma, Gastric
      • Neoplasm, Breast
      • Taipei, Taiwan
      • +1 more
      Nov 2, 2022

      HER2-positive Early Breast Cancer Trial in Germany (Trastuzumab deruxtecan, Standard-of-Care)

      Not yet recruiting
      • HER2-positive Early Breast Cancer
      • Munich, Bavaria, Germany
      • +11 more
      Jan 19, 2023

      Breast Cancer; HER2-positive; Metastatic Trial in Worldwide (Trastuzumab deruxtecan, Placebo, Taxane)

      Recruiting
      • Breast Cancer; HER2-positive; Metastatic
      • Trastuzumab deruxtecan
      • +4 more
      • Phoenix, Arizona
      • +329 more
      Jan 10, 2022

      Gastric Cancer Trial in Philadelphia (Neratinib Pill, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

      Suspended
      • Gastric Cancer
      • Neratinib Pill
      • Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
      • Philadelphia, Pennsylvania
        Fox Chase Cancer Center
      Jul 6, 2022

      Metastatic Breast Cancer, Chemo-induced Alopecia Trial in Boston (Paxman Scalp Cooling System, Eribulin, Sacituzumab govitecan)

      Recruiting
      • Metastatic Breast Cancer
      • Chemotherapy-induced Alopecia
      • Paxman Scalp Cooling System
      • +3 more
      • Boston, Massachusetts
      • +1 more
      Jan 18, 2022

      Reporting of Antibody-Drug Conjugate Associated Sepsis-related

      Completed
      • Sepsis (SMQ)
      • +2 more
      • Antibody-Drug Conjugate
      • Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
      • Changsha, Hunan, China
        Central South University
      Jun 19, 2022

      Metastatic Cancer Trial in Spain (Tumor and Blood sample collection)

      Recruiting
      • Metastatic Cancer
      • Tumor and Blood sample collection
      • Badalona, Barcelona, Spain
      • +14 more
      Jan 23, 2023

      Adenocarcinoma Gastric Stage IV With Metastases, Adenocarcinoma - GEJ Trial in Worldwide (Trastuzumab deruxtecan)

      Active, not recruiting
      Has Results
      • Adenocarcinoma Gastric Stage IV With Metastases
      • Adenocarcinoma - GEJ
      • Trastuzumab deruxtecan
      • Duarte, California
      • +36 more
      Jan 24, 2022

      HER2-positive Breast Cancer Trial in Amsterdam (Trastuzumab deruxtecan)

      Not yet recruiting
      • HER2-positive Breast Cancer
      • Trastuzumab deruxtecan
      • Amsterdam, Netherlands
        Antoni van Leeuwenhoek
      Aug 7, 2023

      Breast Cancer Trial (Patritumab deruxtecan, Chemotherapy, Letrozole)

      Recruiting
      • Breast Cancer
      • Patritumab deruxtecan
      • +2 more
      • Barcelona, Spain
        Hospital Clinic de Barcelona
      Nov 28, 2022

      Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult Trial (Patritumab deruxtecan)

      Not yet recruiting
      • Metastatic Breast Cancer
      • +2 more
      • Patritumab deruxtecan
      • (no location specified)
      May 9, 2023

      HER2-mutant NSCLC Trial in China (Trastuzumab deruxtecan)

      Recruiting
      • HER2-mutant Non-Small Cell Lung Cancer
      • Trastuzumab deruxtecan
      • Baoding, China
      • +29 more
      Jul 20, 2022